Drug Trial Radar · NCT06183931
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,182
Actual
Start
Jan 11, 2024
Primary completion
Dec 6, 2027
Study completion Apr 5, 2028
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.
Conditions
- Transthyretin Amyloid Cardiomyopathy
Interventions
ALXN2220Drug
Participants will receive ALXN2220 via IV infusion.
PlaceboDrug
Participants will receive placebo via IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Occurrence of ACM and CV clinical events during the Blinded Treatment PeriodTime frame: Baseline up to the end of study (up to Month 48)
Locations
213 sites in 27 countries. Site status is shown where the registry gives one.
Research Site
Irvine, California
Research Site
La Jolla, California
Research Site
Palo Alto, California
Research Site
San Francisco, California
Research Site
Aurora, Colorado
Research Site
Washington D.C., District of Columbia
Research Site
Jacksonville, Florida
Research Site
Weston, Florida
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Chicago, Illinois
Research Site
Indianapolis, Indiana
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Kansas City, Missouri
Research Site
St Louis, Missouri
Research Site
New York, New York
Research Site
New York, New York
Research Site
Stony Brook, New York
Research Site
Chapel Hill, North Carolina
Research Site
Durham, North Carolina
Research Site
Cleveland, Ohio
Research Site
Columbus, Ohio
Research Site
Portland, Oregon
Research Site
Danville, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Charleston, South Carolina
Research Site
Greenville, South Carolina
Research Site
Memphis, Tennessee
Research Site
Fort Worth, Texas
Research Site
Houston, Texas
Research Site
Salt Lake City, Utah
Research Site
Falls Church, Virginia
Research Site
Richmond, Virginia
Research Site
Seattle, Washington
Research Site
Madison, Wisconsin
Research Site
Buenos Aires, Argentina
Research Site
CABA, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Showing 40 of 213 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.